Metabolic dysfunction and alcohol associated liver disease
MONDO:0957896A steatotic liver disease characterized by at least one of the five cardiometabolic risk factors for MASLD and alcohol consumption of 140-350g/week (females) or 210-420g/week (males). This disease is distinguished from MASLD by increased alcohol consumption and from ALD by the evidence of one or more of the MASLD cardiometabolic risk factors.
10 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Could a diabetes drug curb alcohol cravings and save livers?
Disease control Recruiting nowThis study tests whether tirzepatide, a drug approved for weight management, can help people with alcohol use disorder and related liver disease drink less and improve liver health. 120 adults will receive weekly injections of tirzepatide or a placebo for 12 weeks. Researchers wi…
Phase: PHASE2 • Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA) • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
AI chatbot aims to curb drinking in liver disease patients
Symptom relief Recruiting nowThis study tests whether a chatbot powered by large language models can help people with metabolic alcohol-related liver disease (MetALD) reduce their alcohol intake. About 50 adults in Hong Kong will use the chatbot for counseling. The main goal is to see if the approach is prac…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New drug tested in patients with fatty liver and cirrhosis
Knowledge-focused Recruiting nowThis early-stage study tests a single dose of an experimental drug called efimosfermin alfa in 32 adults with fatty liver disease and varying degrees of liver damage. The goal is to see how the drug moves through the body and whether it is safe. Participants must have liver cirrh…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC